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ABSTRACT
PREDICTED 25-HYDROXYVITAMIN D SCORE AND RISK OF MULTIPLE
SCLEROSIS IN U.S. WOMEN
MAY 2015
ALEXANDRA C. PURDUE-SMITHE, B.S., UNIVERSITY OF MASSACHUSETTS
AMHERST
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Elizabeth Bertone-Johnson
Multiple sclerosis (MS) is a progressive, autoimmune neurodegenerative disorder
affecting nearly 350,000 people in the United States and resulting in significant disability.
As an immunomodulator, vitamin D may play a role in the development of MS. Previous
studies have observed an inverse association of 25-hydroxyvitamin D (25(OH)D) levels
and MS risk in younger populations; however, whether this relationship persists in older
adults remains unclear. We prospectively investigated the association between predicted
25(OH)D level and incident MS in the Nurses’ Health Study (NHS) (n=121,701) and
NHS II (n=116,430). 25(OH)D levels were predicted using validated regression models
that include important determinants of vitamin D status, including race, UV-B flux (based
on state of residence), physical activity, body mass index, dietary vitamin D intake,
alcohol consumption and post-menopausal hormone use. Data on these factors were selfreported on NHS and NHS II questionnaires starting in 1986 and 1991, respectively, and
updated every 2-4 years. MS diagnoses were ascertained by self-report and confirmed by
medical records. Cox proportional hazards models adjusted for age, ethnicity, latitude of
residence at age 15, and BMI at age 18 were used to estimate hazard ratios (HR)s and
95% confidence intervals (CI)s in each cohort. During up to 18 years of follow-up, we
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documented 179 definite/probable cases of MS with first symptoms after baseline.
Multivariable HRs comparing highest and lowest quintiles of predicted 25(OH)D were
1.09 (95% CI: 0.40-2.96) in the NHS and 0.52 (95% CI: 0.28-0.95) in the NHS II. Higher
predicted plasma 25(OH)D may be modestly associated with lower risk of MS, primarily
in younger women.
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CHAPTER 1
INTRODUCTION
Multiple sclerosis (MS) is a neurodegenerative disorder currently affecting an
estimated 350,000 people in the United States.1 The incidence of MS is relatively low
among adolescents (0.43 per 1,000) and individuals older than 60 (2.88 per 1,000).
Highest incidence occurs in individuals 35 to 39 years of age.2 The risk of developing MS
is 1.5 to 2.53 times higher in women compared to men; the sex-specific incidence rate for
women is estimated to be 5.3 per 1,000 compared to 2.3 per 1,000 in men.2 Additionally,
risk of MS is also higher among white individuals compared to black individuals.4
MS is an autoimmune disorder in which inflammation of the central nervous
system causes progressive degradation of the myelin sheath.5 Two clinical courses of the
disease have been identified. Approximately 85% of MS cases are considered to be
relapsing-remitting MS (RRMS), characterized by an evolution of neurologic dysfunction
over the course of days to weeks, which subsequently plateaus and resolves.5 These
attacks are considered to be the inflammatory phase of the disease, which is followed by
the secondary progressive stage (SPMS) 10-15 years after initial onset in about 50-60%5
of patients. In the relapsing-remitting phase of MS, patients often experience ataxia, optic
neuritis, muscle weakness and numbness as a result of inflammatory lesions affecting
brain, optic nerve and spinal cord.5 As lesions accumulate over a series of relapses,
degradation continues as the patient enters the secondary progressive stage, resulting in
worsening and non-remitting leg weakness, dementia, ataxia and spasticity, along with
other neurological symptoms.1,5 Roughly 10% of cases have primary progressive multiple
sclerosis (PPMS), experiencing the degenerative phase from outset without an initial
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relapsing-remitting inflammatory phase.5 The progression of MS results in substantial
disability.6
Established risk factors for MS include infection by Epstein-Barr virus, cigarette
smoking, high body mass index at age 18 and genetic predisposition.3,7 There are several
genes associated with increased risk of MS. The most prominent genetic risk factor for
MS is the HLA-DRB1*1501 risk allele; in individuals of northern European descent, this
haplotype confers a 3-fold risk in MS.8 Prior studies have found no evidence to suggest
that micronutrients other than vitamin D are associated with MS.9

Vitamin D Hypothesis
Vitamin D plays in an important physiologic role in calcium and blood pressure
regulation, neurodevelopment and modulation of immune response.4 The primary form of
vitamin D (colecalciferol) comes from both sun exposure and dietary sources including,
but not limited to fatty fish, fortified foods such as milk, and supplements.4 Sunlight
exposure provides significantly more vitamin D than dietary sources. For example, 20
minutes of sun exposure during the summer months provides 10,000 IU of vitamin D
compared to 400 IU from 1 serving of fatty fish.4
Ecologic studies have observed a latitude gradient of MS risk, with higher
incidence rates occurring with increasing latitude.10 Data from such studies have given
rise to the hypothesis that the gradient in incidence rates may be explained by differential
sun exposure and therefore, vitamin D exposure.4
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Vitamin D Metabolism
Cutaneous synthesis of vitamin D occurs as UVB radiation from sunlight reacts
with 7-dehydrocholesterol in the skin, forming pre-vitamin D and then cholecalciferol.4
Cutaneous and dietary cholecalciferol are hydroxylated in the liver to 25-hydroxyvitamin
D and later converted to 1,25-dihydroxyvitamin D by the kidney and target tissues.11
The action of circulating 1,25-dihydroxyvitamin D is mediated by the vitamin D
receptor (VDR), which regulates the expression of vitamin D responsive genes.12 Because
VDR expression has been observed in central nervous system tissue, it has been
hypothesized that this may be a site of vitamin D activity.12
Increasing circulating levels of 1,25-dihydroxyvitamin D may activate VDR in
the central nervous system.11 Activation of VDR in immune cells and neurons causes a
decrease in the inflammatory response of T-helper-1 cells and an increase in the antiinflammatory response of T-helper-2 cells.11 Considering that MS is an inflammatory
immune reaction of the central nervous system, increased VDR activation due to
increased circulating 1,25-dihydroxyvitamin D may modulate the regulatory function of
T cells, thereby protecting an individual from inflammation of central nervous tissue. In
clinical studies of MS patients, significant correlations between serum 25hydroxyvitamin D and activity of T cells have been reported.13,14

Epidemiology of Vitamin D and Multiple Sclerosis
Six prior epidemiological studies have directly investigated the association of
vitamin D (dietary9 or serum 25(OH)D15-19) and MS. Three of these studies were
prospective9,15,16 (two nested case-control15,16) and three were case-control studies.17-19 Of
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the retrospective case-control studies, two reported an inverse association17,18 of serum
25(OH)D and MS, and one reported no association.19 While the results of two casecontrol studies support an association of vitamin D and MS, the greatest limitation of the
case-control study design is the collection of serum measurements after MS diagnosis. It
is possible that lower vitamin D levels among cases are a consequence of MS, rather than
an etiologic factor. Therefore, the primary way in which reverse causation can be
eliminated in epidemiologic investigations is through prospective analyses.
In the best-designed study, Munger et al used a prospective, nested case-control
study design to evaluate serum 25(OH)D level and risk of MS among 7 million U.S.
service-men and -women whose blood samples and medical records make up the
Department of Defense Serum Repository (DoDSR).15 The study used at least two serum
25(OH)D measurements from blood samples drawn after entry into the military and prior
to a probable/definite diagnosis of MS. In the analyses, 257 incident cases of MS were
matched to 514 healthy controls according to age, sex, race/ethnicity, date of sample
collection and branch of military service. The race-stratified results indicated a
statistically significant inverse association for white men and women whose serum
25(OH)D level fell into the highest quintile (OR=0.38; 95% CI: 0.19-0.75). Among
blacks, serum 25 (OH)D in the highest tertile was not associated with MS (OR=1.05;
95% CI: 0.51-2.17). Among Hispanics, the OR of serum 25(OH)D >100 nmol/L
compared to serum 25(OH)D <75 nmol/L was not statistically significant (OR=0.61;
95% CI: 0.13-2.93). This was the first study to use repeated 25(OH)D measurements to
assess vitamin D status prior to MS diagnosis.
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In another prospective study conducted by Munger et al, dietary vitamin D intake
was also found to be inversely associated with MS risk within the Nurses’ Health Study
(NHS) (n=92,253) and Nurses’ Health Study II (NHS II) (n=95,310).9 Vitamin D was
assessed using food frequency questionnaires (FFQ) administered every two years, from
which total vitamin D intake and supplemental vitamin D was estimated. Multiple
sclerosis cases (n=173) through the year 1998 were ascertained by self-report on biennial
questionnaires and confirmed as a probable/definite diagnosis by a physician. In the
NHS, total vitamin D intake in the highest quintile was inversely associated with risk of
multiple sclerosis (RR=0.41; 95% CI: 0.18-0.94) as compared to the lowest quintile. In
the NHS II, total vitamin D intake in the highest quintile was non-significantly inversely
associated with risk of MS (RR=0.83; 95% CI:0.41-1.67). However, in both the NHS and
NHS II, the trend across quintiles was not statistically significant (p-trend= 0.16 and ptrend=0.13, respectively). One limitation of this study was that dietary intake of vitamin
D alone may not the most reliable estimate of circulating, bioavailable vitamin D due to
the substantial effect of sunlight on serum 25(OH)D levels.
In order to assess the association of vitamin D and MS in the NHS and NHS II,
we were interested in using a more comprehensive exposure assessment of vitamin D that
incorporated other contributing factors of vitamin D status. Using the NHS and NHS II
cohorts provided an excellent opportunity to investigate the association of vitamin D and
MS in older women, which the Munger et al DoDSR study was not able to do. Our study
was conducted in the same population as the dietary vitamin D study conducted by
Munger et al; however, in our analyses, by using predicted 25(OH)D scores, we were
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able to use a more comprehensive exposure assessment than dietary vitamin D intake
alone.
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CHAPTER 2
METHODS
Study Design
We prospectively assessed the association between predicted 25(OH)D score and
risk of MS within the Nurses’ Health Study and Nurses’ Health Study II.
Study Population
The NHS was established in the United States in 1976, when 121,701 married,
registered nurses ages 30-55 from 11 states responded to a mailed questionnaire
regarding lifestyle habits, health behaviors and medical history. The NHS II includes
116,430 female registered nurses ages 25-42 in the United States who responded to a
similar initial questionnaire mailed in 1989. Participants of both cohorts are mailed
biennial follow-up questionnaires that assess disease risk factors, new disease diagnoses
and significant medical events.
Participants of the NHS were recruited from the registry of the American Nurses’
Association according to the age and marital status eligibility criteria. Participants of the
NHS were selected from the following 11 states: New York, California, Pennsylvania,
Ohio, Massachusetts, New Jersey, Michigan, Texas, Florida, Connecticut, and Maryland,
representing the states with the largest number of registrants. Participants of the NHS II
were recruited from 14 state nursing boards and were eligible if they met the age criteria
and were excluded if they did not provide a social security number or alternative contact
person. Participants of the NHS II were selected from the following states: California,
Connecticut, Indiana, Iowa, Kentucky, Massachusetts, Michigan, Missouri, New York,
North Carolina, Ohio, Pennsylvania, South Carolina, and Texas.
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For the present analysis, we excluded women who died prior to baseline or who
were missing baseline exposure information. Additionally, we excluded women
developing MS who were missing date of first symptoms or who experienced symptom
onset prior to baseline. (Table 1) After exclusions, 74,914 individuals in the NHS and
95,106 individuals in the NHS II were included in the main analyses and contributed
26,223,875 and 22,658,634 person-months of follow-up, respectively. In this analysis, 39
women in the NHS and 140 women in the NHS II became incident probable/definite MS
cases during follow-up.

Predicted 25-hydroxyvitamin D Scores
Serum 25(OH)D measurement is considered the “gold standard” approach to
assessing vitamin D status. However, it is highly variable by season of blood draw and
recent sun exposure.20 Reproducibility of serum measurements is relatively high across 23 year intervals, but decreases over longer time periods. In the NHS, the intra-class
correlation coefficient (ICC) for plasma 25(OH)D measured 2-3 years apart is 0.72.
However, over 10-11 years, the correlation coefficient drops to 0.5, reflecting decreasing
reliability with increasing time.20
Long-term vitamin D status may be a better predictor of chronic disease risk;
however, the expense and difficulty of obtaining repeated measures of serum 25(OH)D in
a large prospective cohort study often limits feasibility. Ideally, in a prospective study,
we would collect samples and measure serum 25(OH)D for all participants over each
follow-up cycle; however, this is unrealistic given budgetary and logistic constraints.
While plasma 25(OH)D measurements are available for a small subset of participants in
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the NHS and NHS II cohorts, only 57 cases provided a blood sample prior to MS
diagnosis.
Because of the limitations of using directly measured 25(OH)D levels to assess
the association of vitamin D and MS risk, we have instead used predicted 25(OH)D level
as the exposure assessment. The purpose of using predicted scores in lieu of serum
measurements was two-fold. First, it enabled us to capture changes in predictors of
vitamin D status over longer time periods prior to MS onset. Using predictors of serum
25(OH)D as a proxy for actual serum measurements allowed us to look at a longer
potentially relevant etiologic time period. Second, it allowed for increased sample size of
eligible cases and greater power to assess a potential difference in the association of
vitamin D and MS in older versus younger women.

Development of Predicted 25-hydroxyvitamin D Scores
For both the NHS and NHS II, Bertrand et al created predicted 25(OH)D scores
based on correlates of vitamin D status measured from biennial follow-up
questionnaires.20 The scores were derived using the following covariates: race (white,
black, other), energy-adjusted vitamin D intake from food sources (≥ 400, 300-399, 200299, 100-199, <100 IU/d), vitamin D from supplements (≥ 400, 200-399, 1-199, 0 IU/d),
UVB-flux based on latitude of state of residence (<113°, 113°, >113°), BMI (<22, 2224.9, 25-29.9, 30-34.9, >35 kg/m2), physical activity (quintiles), alcohol intake (0, 1-4.9,
5-9.9, 10 g/day), and hormone use (pre-menopausal, post-menopausal/unknown PMH,
post-menopausal/never PMH, post-menopausal/past PMH, post-menopausal/current
PMH). Race was included as a predictor as a proxy for skin tone. Alcohol intake and
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energy-adjusted vitamin D intake from food sources and supplements was estimated from
food frequency questionnaires that asked participants to estimate their average frequency
of consumption of specific foods over the preceding 12 months. UVB flux for state of
residence was an estimated composite of average UVB radiation based on latitude,
altitude and cloud cover. Physical activity in MET-hours/week was estimated from
nurses’ responses to questions regarding activity frequency and intensity on follow-up
questionnaires and was used as a proxy for time spent outdoors.
For each cohort, these covariates, along with age, season of blood draw and
laboratory batch, were regressed as a linear function to predict serum 25(OH)D in a
“training sample” of nurses (NHS n=2,079; NHS II n=1,497) who had available blood
and had served as controls for all previous and ongoing nested case-control studies of
vitamin D within the cohorts. Covariate information from the questionnaire cycle closest
to the date of blood draw was used in the prediction model building. The regression
coefficients for each covariate in this model were used to quantify predicted scores for
participants of each cohort. (Table 2) Season of blood draw was not included in the
derived scores because it does not affect long-term within-person variation of serum
25(OH)D.
For the NHS, predicted scores for each cycle of follow-up were derived for all
living participants beginning in 1986 (the first year of comprehensive physical activity
measurement and estimate of UVB-flux). Dietary and supplemental vitamin D estimates
from FFQs (assessed every four years) were carried forward from the previous FFQ for
non-FFQ years. In the event that a participant had incomplete data on a predictor from a
follow-up questionnaire, values from the previous cycle were carried forward one cycle
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(with the exception of menopausal status/PMH use). UVB flux was not assessed in 2004;
therefore, the value from 2002 was used. For participants who were missing data on a
specific predictor for more than one follow-up cycle and for those who did not respond at
all to the follow-up questionnaire during a cycle, a prediction score was not created and
participants did not contribute to person-time in this cycle.
For the NHS II, prediction scores were created similarly, using the same set of
predictors assessed from biennial follow-up questionnaires. The first year of derivation
was 1991; scores were derived for all women who responded to the 1991 questionnaire
and FFQ and were derived for each questionnaire year thereafter through 2003. For
questionnaire years 2005 and 2007, predicted scores from 2003 were carried forward.
Missing data on individual predictors were carried forward, as described for the NHS
cohort.

Validity of the Prediction Model
A separate, independent “test sample” of nurses in each cohort with available
plasma 25(OH)D measurements from a more recent nested case-control study was used
to validate the scores estimated by the “training sample” data set. Bertrand et al compared
derived scores for the “test sample” that were estimated from the regression coefficients
of the “training sample” model to actual plasma 25(OH)D measurements.
The validity of the predicted 25(OH)D scores in the NHS and NHS II was
evaluated by comparison to plasma 25(OH)D levels in the aforementioned “test sample”
of participants of each cohort (NHS, n=818; NHS II, n=479).20 The Spearman correlation
coefficients between predicted score and plasma 25-hydroxyvitamin D level adjusted for
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season, batch, and age were 0.33 and 0.42 for the NHS and NHS II, respectively.20 For
NHS, the prediction model explained 33% of the variability in plasma 25(OH)D. For
NHS II, the prediction model explained 25% of serum 25(OH)D variability.20

Assessment of Multiple Sclerosis
Documentation of incident MS cases in the NHS and NHS II was initiated by selfreport of new diagnosis on one of the biennial follow-up questionnaires. In the event that
a nurse indicated a new diagnosis, she was asked permission by investigators to contact
her treating physician or neurologist and review medical records. Upon obtaining
permission, the physician or neurologist was sent a questionnaire, which addressed the
following aspects of the diagnosis: certainty of diagnosis (definite, probable, possible, or
not MS), date of symptom onset, laboratory test results, attack history, type of MS and
other relevant information pertaining to the diagnosis. Diagnoses were classified as
definite, probable, possible, or not MS according to Poser MS diagnostic criteria.21
Definite cases were defined as clinically definite or laboratory-supported definite MS.
Probable cases were defined as clinically probable or laboratory-supported probable MS.
For the purposes of this analysis, we included only incident definite/probable MS cases in
the main analyses. Cases were ascertained in two-year follow-up intervals.
MS was first included as physician diagnosed condition on the 1992 (NHS) and
1991 (NHS II) questionnaires. Since it is possible that MS may cause an individual to
modify behaviors associated with the variables contributing to the 25(OH)D score, MS
cases in the NHS who experienced symptom onset prior to the first available prediction

12

scores in 1986 and MS case in the NHS II who experienced symptom onset prior to 1991
were excluded.
Validity of Multiple Sclerosis Assessment
The validity of MS case ascertainment within the NHS and NHS II has been
previously described by Hernan et al.21 Briefly, the medical records of a small sample of
MS cases (n=39) were reviewed by study neurologists blinded to the diagnosis
classification assigned by the nurses’ treating neurologist. Among probable/definite
diagnoses from treating neurologists, classification with study neurologists was
concordant 93% of the time. Therefore, diagnoses from the nurses’ treating neurologists
were used in determining diagnosis classification for all MS cases. In the event that a
nurse’s diagnosis from her treating neurologist was not available, the study neurologist
made the diagnosis after a review of medical records.

Covariate Assessment
Information regarding BMI, latitude of residence, and race was obtained from
baseline questionnaires and were updated every two years from returned follow-up
questionnaires. Because the aforementioned covariates were included in the prediction
models for this exposure, to avoid over-adjustment, they were not included as covariates
in the analyses. Instead, we adjusted for age9,15, cigarette smoking (pack-years)9, latitude
of residence at age 15 (North: ≥41° latitude, Middle: 37-<41° latitude, South: <37°
latitude)9, BMI at age 18 (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2)3, and ethnicity (Southern
European, Scandinavian, other Caucasian and other), based on inclusion in prior studies.
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BMI at age 18, latitude of residence at age 15, and ethnicity was assessed at baseline
(1976, NHS; 1989, NHS II). Smoking was updated for each follow-up cycle.

Statistical Analysis
First, we calculated general descriptive statistics of the distribution of predicted
25(OH)D score in the NHS and NHS II. (Table 3) To evaluate confounders, we crosstabulated covariates by age-adjusted mean predicted 25(OH)D score at baseline (1986
and 1991, respectively). (Table 4) Generalized linear models were used to assess ageadjusted mean scores by covariates. Person-months were calculated from month of return
of baseline questionnaire to month of MS symptom onset, death from any cause, or end
of follow-up (2004 for NHS and 2009 for NHS II), whichever occurred first.
Analyses were conducted separately for each cohort (NHS and NHS II). Cox
proportional hazards models were used to evaluate the association between predicted
25(OH)D score and MS, adjusting for covariates. To assess predicted 25(OH)D score and
risk of MS, predicted scores were analyzed as a categorical variable (quintiles). Hazard
ratios and 95% confidence intervals are reported. (Table 5) Mantel extension tests were
used to assess trend across quintiles.
A sensitivity analysis was conducted restricting to only definite MS cases. Ageadjusted and multivariable Cox proportional hazards models were repeated excluding
probable cases. Hazard ratios and associated 95% confidence intervals are reported.
(Table 6)	
  All analyses were conducted using SAS v9.3 (SAS Institute Inc, Cary, NC).
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CHAPTER 3
RESULTS
Table 3 shows the distribution of predicted scores in each cohort at baseline.
Mean predicted 25(OH)D score was lower in the NHS than in the NHS II. In the NHS,
scores in the lowest quintile ranged from 2.49 to 24.44, which was a greater range than
any other quintile. The same was true in the NHS II; scores in the lowest quintile ranged
from 14.48 to 28.55. The average age of symptom onset of cases was 54 years in the
NHS and 45 years in the NHS II.
Because of high statistical power in this analysis, even small differences in the
distribution of all covariates according to age-adjusted mean predicted 25(OH)D scores at
baseline were statistically significant. (Table 4) In the NHS, women who were 55-59
years old at baseline had the lowest mean predicted 25(OH)D score and women who
were 45-49 years old at baseline had the highest mean predicted 25(OH)D score. Baseline
mean 25(OH)D score was highest amongst women younger than 30, and lowest amongst
women older than 45 in the NHS II. In both the NHS and NHS II, women of
Scandinavian ethnicity had highest mean age-adjusted predicted score and women of
“other” ethnicity had the lowest. Women who reported BMI at age 18 greater than 30
kg/m2 had the lowest predicted age-adjusted mean score in both cohorts. In the NHS,
women who had a middle latitude of residence at age 15 had the lowest age-adjusted
mean predicted 25(OH)D score at baseline, while those who had a southern latitude of
residence at age 15 had the highest. In the NHS II, age-adjusted mean 25(OH)D score
was lowest for southern latitude of residence at age 15 and highest for northern latitude.

15

In both cohorts, age-adjusted mean 25(OH)D score was lowest for women who smoked
greater than 25 packs per year.
Table 5 shows age-adjusted and multivariable-adjusted hazard ratios of MS by
quintile of predicted 25(OH)D score. In the NHS, comparing Q5 vs. Q1 of predicted
25(OH)D score was not associated with risk of MS (HR=1.15, 95% CI=0.42-3.12) (ptrend=0.97). However, in the NHS II, women in the highest quintile (median=34.76) of
predicted 25(OH)D had a significant lower risk of developing MS (HR=0.52, 95%
CI=0.28-0.95), with some evidence of a linear trend (p-trend=0.07).
Table 6 shows age-adjusted and multivariable-adjusted hazard ratios of MS by
predicted 25(OH)D score in analyses restricted to definite cases. In the NHS, results were
somewhat stronger in analyses limited to definite cases, though our power for this
comparison was low and the trend was not significant (p-trend=0.47). Women in the
highest quintile of predicted score had a non-significant lower risk of MS (HR=0.58, 95%
CI=0.13-2.57). In the NHS II, the inverse association was stronger when restricted to
definite cases. For example, women in the highest quintile of predicted score experienced
a 59% lower risk of developing MS as compared to those in the lowest quintile
(HR=0.41, 95% CI=0.20-0.85). The linear trend was also significant (p-trend=0.04).
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CHAPTER 4
DISCUSSION
We observed an inverse association of predicted 25(OH)D score and risk of MS
in the NHS II with some evidence of a dose-response relationship, although this
association was not observed in the NHS. This difference may be due to variation in the
association across age groups.
The findings of our study in the NHS II cohort are consistent with prior literature
in younger adults. Although no prior studies have used a predicted 25(OH)D score as a
proxy for vitamin D status, one prospective study of serum 25(OH)D and one prospective
study of dietary vitamin D intake found a similar association. In a nested case-control
study of U.S. service-men and –women, Munger et al reported a 62% lower risk of MS in
white individuals in the highest quintile of serum 25(OH)D compared to those in the
lowest quintile. In this population, the average age of MS onset was 28.5 years, which is
closer to the age during follow-up of NHS II members than NHS members. For the NHS,
the youngest possible age at start of follow-up in our study was later (40 years) compared
to the NHS II (27 years). Earlier cases in the NHS were excluded because of the timing of
the start of the prediction modeling in 1986, making this an older cohort during the
exposure window than the NHS II. In the NHS, the average age of onset was 54, which
may have contributed to the lack of association for this cohort.
In a prospective study of dietary vitamin D intake in the NHS and NHS II,
Munger et al found that total dietary vitamin D intake in the highest quintile was
associated with a 59% decreased risk of MS in the NHS (RR=0.41; 95% CI: 0.18-0.94).
In the NHS II, total dietary vitamin D intake in the highest quintile was associated with a
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17% decreased risk of MS (RR=0.83; 95% CI: 0.41-1.67). In the NHS, among the four
cases with supplemental vitamin D ≥ 400 IU/day, there was a 65% decreased risk of MS
compared to non-supplement users with a non-significant trend (p-trend=0.10). In the
NHS II, among the 14 cases with supplemental vitamin D ≥ 400 IU/day, there was 30%
decreased risk of MS compared to non-supplement users and the trend was not significant
(p-trend=0.18).
One reason that Munger et al may have found a strong inverse association of
dietary vitamin D intake and MS in the NHS cohort while our study did not may be due
to the younger cases included in their analysis. By design, our study excluded all cases of
MS that experienced symptom onset prior to 1986 (the first year of available predicted
scores), meaning that the youngest possible age of MS cases included in our analysis was
40. Their study included cases collected from 1980 to 1998, which means that the
youngest possible cases included in their analysis was 34. This discrepancy in the age of
cases may partially explain the strong inverse association of dietary vitamin D intake in
the NHS that Munger et al found while we observed no association. The lack of
association that we observed in the NHS (older women) and the strong inverse
association that we observed in the NHS II (younger women) is consistent with the
highest incidence rates occurring in younger women and lower incidence rates occurring
with increasing age.
In the NHS II, results from this study are consistent with ours; however, we
observed an even stronger association than Munger et al and our results were statistically
significant. The non-significant findings in the NHS II that Munger et al observed for
dietary vitamin D intake may have been affected by non-differential misclassification of
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the exposure. Because vitamin D status is influenced by a variety of different factors
(particularly sun exposure), dietary vitamin D intake may not be the most reliable of
vitamin D status. In our study, by using predicted 25(OH)D scores as a proxy for vitamin
D status rather than dietary vitamin D intake alone, other predictors of vitamin D status
were incorporated into the exposure, reducing non-differential misclassification. This
may explain the stronger results we observed in the NHS II compared the dietary vitamin
intake study.
Our study has several strengths. First, in prospective cohorts of 121,701 and
116,430 women, there were 26,223,875 and 22,658,634 person-months of follow-up
contributed in the NHS and NHS II, respectively. Follow-up for each questionnaire cycle
is at least 89% and is even higher for prospective analyses and thus, selection bias due to
differential follow-up in this study is unlikely. Another strength of our study is that we
were able to censor MS cases at date of first symptoms. MS cases often experience first
symptoms long before physician diagnosis. Symptoms of MS, which are exacerbated by
heat, may have induced behavior change related to vitamin D exposure before date of
diagnosis and thus, censoring at date of symptom onset rather than date of diagnosis
reduces the potential for reverse causation. In our study, because predicted 25(OH)D
scores are updated biennially, we were able to capture changes in exposure status
throughout the duration of follow-up. By using the NHS and NHS II cohorts, we were
able to assess the association of vitamin D status and risk of MS in older adult women
using a proxy of vitamin D status, an association that has not previously been elucidated.
Because repeated 25(OH)D measurements are not available for most cohorts, the
use of predicted 25(OH)D scores as a proxy for blood measurements is a practical and
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cost-effective way to assess the association between vitamin D and MS. Using predicted
25(OH)D scores in lieu of serum measurements may best be viewed as a trade-off of
strengths. By using updated predicted scores in prospective analyses as a proxy for serum
measurements, we sacrificed direct measurements but gained the ability to prospectively
assess vitamin D over a longer time period prior to MS onset.
There are also some limitations to our study. Predicted 25(OH)D scores were
estimated from self-reported covariates including race, energy-adjusted vitamin D from
food, vitamin D from supplements, BMI, physical activity, alcohol intake and hormone
use.20 It is possible that women may have inaccurately reported some of these covariates,
which may have caused participants to fall into inappropriate quintiles of predicted
25(OH)D score. Several predictors of vitamin D status including skin tone, time spent
outdoors, sunscreen use and genetic polymorphisms (i.e., VDR and VDBP expression)
were not directly measured and incorporated in the derivation of predicted scores.
However, race and physical activity were used as proxy measurements for skin tone and
time spent outdoors, respectively, in an effort to include these factors.
It is important to note that the Spearman correlation coefficients between
predicted scores and serum measurements adjusted for age, batch, and season of blood
draw for the NHS and NHS II are 0.33 and 0.40, respectively. Serum 25(OH)D has
moderate within-person variability, and thus is not a true “gold standard” of vitamin D
status. In the NHS, the intra-class correlation coefficient (ICC) for serum 25(OH)D over
2-3 years is 0.7220, which indicates fairly high reproducibility. However, over 10-11
years, the ICC is 0.5020, indicating decreasing reproducibility with increasing time.
Fitting the predictors to a single serum 25-hydroxyvitamin D measurement likely
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underestimated the correlation coefficients between serum values and predicted scores.
According to Bertrand et al, in a comparison of quintiles of serum 25(OH)D and
predicted 25(OH)D scores, 24.8% of NHS participants and 29.9% NHSII participants fell
into identical quintiles. 59.8% of NHS participants and 66.5% of NHSII participants fell
into the same or adjacent quintiles and only 5% or less of the participants fell into
extreme opposite quintiles.20
Misclassification of the exposure is likely and if present, caused a bias towards
the null. The middle quintiles may have been particularly affected; however, comparison
between extreme quintiles (i.e., low versus high score) is likely a more robust comparison
because of the low rate of misclassification into extreme opposite quintiles. While the
predicted scores do not directly measure vitamin D deficiency/sufficiency per se, their
relative ranking of women into quintiles is likely to be generally accurate for extreme
opposite ends of the spectrum. Women who fell into the lowest quintile of predicted
25(OH)D score likely correspond to women who are truly vitamin D deficient and vice
versa. Importantly, if misclassification of the exposure occurred, we would expect that
the true association would be even stronger than we observed.
It could be argued that null results in the NHS are the result of non-differential
misclassification of exposure rather than a true lack of an association for older women.
However, the difference in Spearman correlation coefficients of serum 25(OH)D and
predicted score between the NHS (r=0.33) and NHS II (r=0.40) is relatively small, and is
unlikely to explain a null association in the NHS considering such a strong inverse
association in the NHS II. It is unlikely that the NHS experienced a much higher degree
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of non-differential misclassification of exposure than the NHS II, and thus, we attribute
the difference in results to a potential variation in the association across age groups.
For the NHS and NHS II, the covariates used to create the prediction scores
accounted for 33% and 25% of the variability in serum 25(OH)D.20 The remaining
unexplained variability can likely be attributed to measurement error of predictor
variables and missing information regarding other determinants of vitamin D status, such
as genetic factors.20 We do not have available information regarding infection of EpsteinBarr virus (a known risk factor for MS) for the entire NHS and NHS II cohorts; however,
this is unlikely to confound the association between predicted 25(OH)D score and MS.
While EBV infection is associated with risk of MS, it is not associated with serum
25(OH)D.7 Additionally, genes associated with increased risk of MS such as HLADRB1*1501, have not been associated with serum 25(OH)D levels.8 Essentially, some of
the remaining variability of serum 25(OH)D unexplained by the covariates of the
prediction scores is likely to be related to genetic factors affecting plasma 25(OH)D, but
these same genetic factors have not been consistently associated with risk of MS.4
Because of this, we expect the effect of confounding by genetic factors to be relatively
small. Other dietary components may interact with vitamin D; however, other vitamins
and minerals have not been consistently associated with risk of MS.9 Therefore, we also
expect the effect of confounding by other dietary factors to be relatively small.
The results of this study are generalizable to other women of similar age in the
United States. The association of predicted 25(OH)D score and MS may differ in
adolescents and thus, findings may not be generalizable to this group.
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CHAPTER 5
CONCLUSION
In conclusion, the results of our study expand upon the existing literature that
supports a protective role of vitamin D on risk of MS. Our analyses suggest that predicted
25(OH)D score, as a proxy for vitamin D status, is associated with lower risk of MS in
younger women; however, this association was not observed in older women.
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TABLES
	
  
Table 1. Exclusion criteria: Nurses’ Health Study & Nurses’ Health Study II
NHS
NHSII
N
N
Original study sample
121,701
116,430
Missing date of first symptoms
14
45
127
111
MS onset prior to first score derivation
2293
5
Death prior to baseline
Missing baseline prediction scores
43193
21163
Final study sample

75,914
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95,106

Table 2. Predictors of serum 25-hydroxyvitamin D from multivariable linear regression
models in the Nurses’ Health Study & Nurses’ Health Study II
Predictor
NHS
P
NHSII
P
n=2079
n=1497
Difference
Difference
in 25(OH)D
in 25(OH)D
(ng/ml; β)
(ng/ml; β)
Intercept
22.69
35.78
Age (years)
0.07
0.07
−0.23
<0.0001
Race
<0.001
<0.001
White
0
0
Black
−11.3
−6.42
Asian
−
−5.55
Hispanic
−
−6.83
Other
−1.63
1.98
UV-B flux category
<0.0001
0.67
1 (highest)
0
0
2
−2.69
−0.16
3
−1.29
−0.66
4
−
−0.6
5 (lowest)
−
−
Dietary vitamin D (µg/d)
<0.0001
0.003
<2.5
0
0
2.5- <5
0.92
1.56
5- <7.5
2.19
1.87
7.5- <10
3.43
3.55
≥10
3.33
2.49
Supplementary vitamin D
(µg/d)
<0.0001
<0.001
0
0
0
0.025- <5
2.85
0.76
5- <10
1.57
2.05
≥10
3.15
2.7
BMI (kg/m2)
<0.0001
<0.0001
< 19
−
2.22
< 22 (19-21.9 in NHS II)
0
0
22-24.9
−0.57
−0.38
25-29.9
−1.95
−2.35
30-34.9
−3.32
−5.09
≥ 35
−8.16
−6.17
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Predictor
Quintile of physical activity
1 (lowest)
2
3
4
5 (highest)
Post-menopausal hormone use
1
2
3
4
5
Alcohol intake (g/d)
0
> 0- <5
5- <10
≥10
Season of blood draw
Autumn
Summer
Spring
Winter
*Table adapted from Bertrand et al20

NHS

P

NHSII

<0.0001
0
1.77
1.15
2.13
3.66

<0.0001
0
0.99
1.2
3.07
3.79

<0.001
0
−1.66
−2.11
−1.17
−0.66

0.12
0
0.17
1.94
1.53
0.71

<0.0001
0
0.24
1.33
2.62

<0.001
0
1.34
2.38
2.69

<0.0001
0
1.18
−2.68
−3.35
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P

<0.0001
0
1.33
−5.55
−5.61

Table 3. Distribution of predicted 25-hydroxyvitamin D scores at baseline: Nurses’
Health Study & Nurses’ Health Study II
N
M (SE)
Range
Median
NHS
Predicted 25hydroxyvitamin D
score

75914

27.30 (0.01)

37.12

27.49

Predicted 25hydroxyvitamin D
score
Q1
Q2
Q3
Q4
Q5

15172
15106
15240
15174
15222

21.60 (0.02)
25.57 (0.01)
27.50 (0.004)
29.39 (0.005)
32.40 (0.01)

21.95
2.14
1.84
2.02
9.13

22.60
25.59
27.49
29.36
32.00

NHS II
Predicted 25hydroxyvitamin D
score

95106

31.20 (0.01)
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31.64

Predicted 25hydroxyvitamin D
score
Q1
Q2
Q3
Q4
Q5

19013
18997
19029
19045
19022

25.92 (0.02)
29.80 (0.005)
31.64 (0.003)
33.23 (0.004)
35.42 (0.007)

14.07
2.26
1.61
1.68
6.38

26.45
29.88
31.64
33.22
35.19
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Table 4. Distribution of covariates according to age-adjusted mean 25-hydroxyvitamin D
score at baseline: Nurses’ Health Study (1989) & Nurses’ Health Study II (1991)
Covariate
NHS
NHS II
Mean 25(OH)D Score (SE)
Mean 25(OH)D Score (SE)
Ethnicity
S. European
Scandinavian
Other caucasian
Other

27.17 (0.04)
28.42 (0.07)
27.68 (0.02)
26.18 (0.03)

31.37 (0.03)
31.81 (0.05)
31.47 (0.01)
27.57 (0.04)

BMI at age 18
<18.5
18.5-24.9
25-29.9
>=30

27.98 (0.04)
27.52 (0.02)
25.26 (0.05)
23.69 (0.07)

32.24 (0.03)
31.42 (0.01)
28.61 (0.04)
26.99 (0.07)

Latitude of residence at
age 15
North
Middle
South

27.79 (0.02)
26.80 (0.02)
28.46 (0.05)

31.32 (0.02)
31.29 (0.02)
31.18 (0.03)

Smoking (pack-years)
Never
<10
10-24
25+

27.26 (0.12)
27.67 (0.03)
27.61 (0.04)
27.13 (0.02)

31.09 (0.01)
31.76 (0.03)
31.24 (0.03)
30.52 (0.06)
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Table 5. Age-adjusted and multivariate HR and 95% CI of multiple sclerosis by quintile
of predicted 25-hydroxyvitamin D score: Nurses’ Health Study & Nurses’ Health Study
II
Person-months
Age-adjusted
Multivariate*
P-trend
Cases (N)
HR (95% CI)
HR (95% CI)
NHS

26,223,875
N=39

P=0.97

Q1

1.0 (Referent)

1.0 (Referent)

Q2

1.24 (0.49-3.13)

1.27 (0.49-3.27)

Q3

0.49 (0.15-1.63)

0.49 (0.14-1.65)

Q4

0.99 (0.37-2.64)

0.97 (0.35-2.67)

Q5

1.13 (0.45-3.01)

1.15 (0.42-3.12)

Q1

1.0 (Referent)

1.0 (Referent)

Q2

0.79 (0.48-1.28)

0.81 (0.49-1.35)

Q3

0.71(0.43-1.17)

0.74 (0.43-1.26)

Q4

0.82 (0.51-1.33)

0.87 (0.51-1.46)

Q5

0.49 (0.28-0.87)

0.52 (0.28-0.95)

NHS II

22,658,634
N=140
P=0.07

*Adjusted for age, ethnicity, latitude of residence at age 15, BMI at age 18 and smoking
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Table 6. Age-adjusted and multivariate HR and 95% CI of multiple sclerosis by
predicted 25-hydroxyvitamin D score restricted to definite cases: Nurses’ Health Study &
Nurses’ Health Study II
Person-months
Age-adjusted
Multivariate*
P-trend
Cases (N)
HR (95% CI)
HR (95% CI)
NHS

26,223,875
N=20

Predicted 25(OH)D
Q1

P=0.47
1.0 (Referent)

1.0 (Referent)

Q2

0.98 (0.28-3.38)

1.00 (0.28-3.55)

Q3

0.39 (0.08-2.00)

0.37 (0.07-2.00)

Q4

0.98 (0.28-3.40)

0.92 (0.25-3.36)

Q5

0.63 (0.15-2.63)

0.58 (0.13-2.57)

1.0 (Referent)

1.0 (Referent)

Q2

0.69 (0.39-1.22)

0.71 (0.39-1.29)

Q3

0.73 (0.41-1.27)

0.76 (0.42-1.39)

Q4

0.73 (0.42-1.28)

0.77 (0.42-1.42)

Q5

0.38 (0.19-0.77)

0.41 (0.20-0.85)

NHS II

22,658,634
N=102

Predicted 25(OH)D
Q1

P=0.04

*Adjusted for age, ethnicity, latitude of residence at age 15, BMI at age 18 and smoking
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